Personalis Stock Earnings Reports

Personalis reported strong clinical adoption of its NeXT Personal MRD test in Q3 2025 with 4,388 clinical tests (26% sequential, 364% year-over-year) and over 700 physicians ordering the assay. Revenue for the quarter was $14.5 million, above guidance, but the company lowered full-year 2025 revenue guidance to $68–73 million due to timing variability in biopharma project samples (including logistical/customs delays) and the lumpy nature of legacy translational research work. Key commercial and clinical highlights: three MolDX coverage dossiers are under review (the company is targeting two coverage decisions in 2025), Phase III and other clinical data (including a reported ~5-month median lead time for MRD detection vs imaging) and the launch of the CATE prospective trial in HR+/HER2- breast cancer. Personalis emphasized that underlying MRD demand remains strong, that Tempus partnership has already met primary volume targets, and that they are expanding in-house commercial capability ahead of Medicare reimbursement. Financially, gross margin was pressured (13.2% in Q3) primarily by lower fixed-cost absorption and investments in unreimbursed clinical testing; excluding those test investments, gross margin would have been ~31%. The company ended Q3 with $150.5 million in cash and short-term investments, expects ~ $75 million cash usage for full-year 2025 and to finish the year with >$130 million cash, and reiterated focus on disciplined spending while investing in clinical volume and reimbursement milestones. Key risks remain biopharma timing variability, reimbursement timing, and operational/logistics issues impacting sample receipt.